Effects of Buyang Huanwu Decoction on Intestinal Barrier, Intestinal Flora, and Trimethylamine Oxide in Rats with Heart Failure

WENG Jie-qiong; LI Jie-bai; YUAN Meng-fei; YAO Ting-ting; ZHANG Jing-fang; ZENG Yuan-yuan; ZHAO Jing; LI Ying; XU Ke; SHEN Xiao-xu

doi:10.1007/s11655-022-2898-z

Your Location：

Home >

Browse articles >

Effects of Buyang Huanwu Decoction on Intestinal Barrier, Intestinal Flora, and Trimethylamine Oxide in Rats with Heart Failure

Original Article | Updated：2023-02-01

- Effects of Buyang Huanwu Decoction on Intestinal Barrier, Intestinal Flora, and Trimethylamine Oxide in Rats with Heart Failure
- Chinese Journal of Integrative Medicine Vol. 29, Issue 2, Pages: 155-161(2023)
- Affiliations：
  
  1.Department of Cardiology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing (100700), China
  2.Department of Nuclear Medicine, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing (100700), China
  3.Peking University Sixth Hospital, Beijing (100700), China
- Author bio：
  
  Prof. SHEN Xiao-xu, E-mail: doctorshen_paper@sina.com.
- Funds：
- DOI：10.1007/s11655-022-2898-z
  CLC：
- Published：2023-02，
  
  Published Online：12 November 2022，
  
  Accepted：13 May 2022
Scan for full text
WENG Jie-qiong, LI Jie-bai, YUAN Meng-fei, et al. Effects of Buyang Huanwu Decoction on Intestinal Barrier, Intestinal Flora, and Trimethylamine Oxide in Rats with Heart Failure. [J]. Chinese Journal of Integrative Medicine 29(2):155-161(2023)
DOI：

WENG Jie-qiong, LI Jie-bai, YUAN Meng-fei, et al. Effects of Buyang Huanwu Decoction on Intestinal Barrier, Intestinal Flora, and Trimethylamine Oxide in Rats with Heart Failure. [J]. Chinese Journal of Integrative Medicine 29(2):155-161(2023) DOI： 10.1007/s11655-022-2898-z.

摘要

Abstract

Objective:

To explore the mechanisms of Buyang Huanwu Decoction (BYHWD) modulating the gut microbiome and trimethylamine oxide (TAMO) to exert cardioprotective effects.

Methods:

Ligation of the left anterior descending coronary artery was performed in rats to induce heart failure (HF). Except for the sham-operation group (

=10)

36 operation-induced models were randomized into 3 groups using a random number table (

=12 in each group): the model group

the BYHWD group (15.02 g/kg BYHWD)

and the positive group (4.99 g/kg metoprolol succinate). After 4-week treatment (once daily by gavage)

echocardiography was applied to evaluate the cardiac function and the Tei index (the ratio of ventricular isovolumic contraction time (IVCT) and isovolumic diastolic time (IVRT) to ejection time (ET)) was calculated; hematoxylin-eosin (HE) staining was observed to characterize the pathology of the myocardium and small intestinal villi. D-lactic acid was detected by an enzyme-linked immunosorbent assay (ELISA). Expressions of occludin

claudin-1

and zonula occludens (ZO-1) were detected by Western blot. 16S ribosomal ribonucleic acid (16S rRNA) sequencing was used to explore the changes in the intestinal flora. TMAO was detected via liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Results:

In the echocardiography

the Tei index was considerably lower in the positive and BYHWD groups compared with the model group (

0.05). Besides

BYHWD improved the pathology of myocardium and small intestine of HF rats and lowered the D-lactic acid content in the serum

when compared with the model group (

0.05). BYHWD also improved the expression of occludin and claudin-1 (

0.05); in the gut microbiota analysis

BYHWD slowed down modifications in the structure distribution of gut microbiota and regulated the diversity of intestinal flora in HF rats. The content of TMAO in the serum was significantly lowered by BYWHT compared with the model group (

0.05).

Conclusion:

BYHWD may delay progression of HF by enhancing the intestinal barrier structure

and regulating intestinal flora and TAMO.

关键词

Keywords

Buyang Huanwu Decoctionheart failureintestinal floratrimethylamine oxide

references

Mentz R, O'Connor C, Granger B, Yang H, Patel C, Steinhauser K, et al. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. Am Heart J 2018;204:202-204.

Maggioni A, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EUR observational research programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808-817.

Mentz R, Cotter G, Cleland J, Stevens S, Chiswell K, Davison B, et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014;16:614-624.

Jin M, Qian Z, Yin J, Xu W, Zhou X. The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med 2019;23:2343-2350.

Ierardi E, Sorrentino C, Principi M, Giorgio F, Losurdo G, Di Leo A. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutrition 2015;4:289-292.

Krack A, Sharma R, Figulla H, Anker S. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005;26:2368-2374.

Romeiro F, Okoshi K, Zornoff L, Okoshi M. Gastrointestinal changes associated to heart failure. Arq Bras Cardiol 2012;98:273-277.

Al-Rubaye H, Perfetti G, Kaski J. The role of microbiota in cardiovascular risk: focus on trimethylamine oxide. Curr Prob Cardiol 2019;44:182-196.

Huntley D, Mollar A, Buesa J, Rodríguez S, Giménez E, Sanchis J, et al. Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?Diag Microbiol Infect Dis 2018;91:141-143.

Troseid M, Andersen GO, Broch K, Hov JR. The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions. EBio Med 2020;52:102649.

Phillips Campbell R, Duffourc M, Schoborg R, Xu Y, Liu X, KenKnight B, et al. Aberrant fecal flora observed in guinea pigs with pressure overload is mitigated in animals receiving vagus nerve stimulation therapy. Am J Physiol-Gastr Liver 2016;311:G754-G762.

Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-1584.

Goodrich J, Davenport E, Clark A, Ley R. The relationship between the human genome and microbiome comes into view. Annu Rev Genet 2017;51:413-433.

Yu W, Gao D, Jin W, Wang Z, Li Y, Peng X, et al. Intestinal flora dysbiosis aggravates cognitive dysfunction associated with neuroinflammation in heart failure. J Card Fail 2020;26:885-894.

Murphy K, O'Donovan AN, Caplice NM, Ross RP, Stanton C. Exploring the gut microbiota and cardiovascular disease.Metabolites 2021;11:493-523.

Nagatomo Y, Tang W. Intersections between microbiome and heart failure: Revisiting the gut hypothesis. J Cardiac Fail 2015;21:973-980.

Mayerhofer C, Awoyemi A, Moscavitch S, Lappegård K, Hov J, Aukrust P, et al. Design of the gut heart-targeting gut microbiota to treat heart failure-trial: A phase Ⅱ, randomized clinical trial. ESC Heart Fail 2018;5:977-984.

Wu XB, Tan YQ, Tian PP, Chen HW, Li J. Systematic evaluation and sequential analysis of the clinical efficacy of Buyang Huanwu Decoction in the treatment of chronic heart failure. Chin J Expl Pharmacoly (Chin) 2021;27:188-195.

Li JB, Yuan HC, Zhao J, Shen XX. Effect of Buyang Huanwu Decoction on intestinal flora and TMAO in rats with heart failure.World J Integr Tradit Chin West Med (Chin) 2020:1814-1818.

Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Transl Res 2021;228:109-125.

Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, et al. Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts. J Am Coll Cardiol 2018;71:1184-1186.

Hunninghake G, Doerschug K, Nymon A, Schmidt G, Meyerholz D, Ashare A. Insulin-like growth factor-1 levels contribute to the development of bacterial translocation in sepsis. Am J Resp Crit Care 2010;182:517-525.

Sun X, Yang Q, Rogers C, Du M, Zhu MJ. AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression. Cell Death Differ 2017;24:819-831.

Manabe A, Furukawa C, Endo S, Marunaka K, Nishiyama T, Fujii N, et al. Chlorpheniramine increases paracellular permeability to marker fluorescein lucifer yellow mediated by internalization of occludin in murine colonic epithelial cells. Biol Pharm Bull 2017;40:1299-1305.

Lam V, Su J, Koprowski S, Hsu A, Tweddell J, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012;26:1727-1735.

Leclercq S, Mian F, Stanisz A, Bindels L, Cambier E, Ben-Amram H, et al. Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun 2017;8:15062.

Cani P, Delzenne N, Amar J, Burcelin R. Role of gut microflora in the development of obesity and. insulin resistance following high-fat diet feeding. Pathol Biol 2008;56:305-309.

Bennett B, de Aguiar Vallim T, Wang Z, Shih D, Meng Y, Gregory J, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013;17:49-60.

Tang W, Wang Z, Fan Y, Levison B, Hazen J, Donahue L, et al. Prognostic value of elevated levels. of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014;64:1908-1914.

Rhee E, Clish C, Ghorbani A, Larson M, Elmariah S, McCabe E, et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 2013;24:1330-1338.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Buyang Huanwu Decoction Ameliorates Damage of Erectile Tissue and Function Following Bilateral Cavernous Nerve Injury

Huoxin Pill (活心丸) Attenuates Cardiac Fibrosis by Suppressing TGF-β1/Smad2/3 Pathway in Isoproterenol-Induced Heart Failure Rats

Metabonomics: A Useful Tool to Reveal Underlying Relationships between Altered Chinese Medicine Syndromes and Ultrafiltration in Treatment of Heart Failure

Effect of Modified Xijiao Dihuang Decoction (加味犀角地黄汤) on Intestinal Flora and Th17/Treg in Rats with Radiation Enteritis

Pathological Relationship between Intestinal Flora and Osteoarthritis and Intervention Mechanism of Chinese Medicine

Related Author

No data

Related Institution

Andrology Laboratory on Integration of Chinese and Western Medicine, Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine

Department of Urology, Huzhou Hospital of Traditional Chinese Medicine

The Second Clinical Medical College, Zhejiang Chinese Medical University

Department of Urology, Affiliated Hospital of Nantong University

Department of Urology, the First People's Hospital of Wenling

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰